Combination therapies could be the future of cancer treatment says new report

Reportbuyer.com has added a new report to it’s catalogue, "Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise", this research provides an overview of the discovery and development of therapeutic drug combinations and multi-target drugs for oncology. The 55 page report states that there is a wave of combination therapies in late stage development that have the potential to revolutionize long-term oncological treatment by addressing the complexities of cancer growth.

Pipeline analysis of the Phase III oncology pipeline focuses on indications such a lung cancer, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, leukemia, lymphoma, head and neck cancer and multiple myeloma. Lung cancer treatments represent the greatest share of the Phase III combination therapy development pool with 16%. This relatively high percentage is not surprising considering the disease's growing prevalence around the world due to an increase in tobacco consumption in emerging economies such as China. The second and third most populous combination therapies in Phase III were breast cancer and colorectal cancer, with 13.4% and 8.5%, respectively.

View the report: "Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise"

press@reportbuyer.com

44 (0) 20 7060 7474

Reportbuyer.com is the online store for global business information. The website now lists more than 200,000 company overviews, market research reports, industry studies and business books from over 300 specialist publishers. Thousands of professionals from across the world make ReportBuyer.com their first choice in their search for quality business insight.

Tags: